Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second-leading cause of cancer-related deaths in Europe by 2040. Unlike other…
Upper Gastrointestinal and Endocrine Tumors Group
Recently presented at the 2024 ASCO Annual Meeting and published in parallel in The Lancet Oncology, results of the OPTIMIZE-1…
The Vall d’Hebron University Hospital Accredited Health Institute (ISS-IR-HUVH) has been one of those selected for the Fortalece -Salud program…
Presented during Presidential session I (1) at the 2023 Congress of the European Society for Medical Oncology (ESMO), 20-24 October…
Now published in EJC – European Journal of Cancer (1), results of a retrospective study led by investigators of VHIO’s…
VHIO has participated in this project coordinated by INCLIVA, which has made it possible to expand knowledge about this type…
Futibatinib, an advanced FGFR inhibitor, has demonstrated effectiveness in impeding tumor growth among patients with FGFR-altered tumors. What is Intrahepatic…
